semaglutide launch Hyderabad-based Natco Pharma Ltd. has received government approval to generic in India, with the rollout expected in March. Semaglutide is widely used for the treatment of Type 2 Alkem Semaglutide India Launch: 2026

Retatrutide has a long half-life estimated at approximately six days based on phase 2 pharmacokinetic data (Jastreboff et al., NEJM 2023) meaning that drug levels rise gradually and remain relatively stable between weekly doses once a steady state is achieved (typically after approximately four to five half-lives, or around four to five weeks of weekly dosing)

initially demonstrated that specific human gut microbial consortia convert ellagic acid into urolithins, thereby highlighting pronounced interindividual variability in metabolite profiles (Reference Cerd, Espn and Parra8)

PT-141 is a manmade substance that mimics natural a-MSH, a melanocortin (1)

March 2012

Targeting cells to help the body make more GLP-1 Another company called Fractyl Health is taking a slightly different approach